Influence of Helicobacter pylori eradicating therapy on endothelial function in patients with coronary heart disease
JIAO Hai-xu
XIA Qing
WANG Feng-yun
GAO De-hong
WANG Yuan
Abstract：Objective To investigate the influence of triple therapy for eradicating Helicobacter pylori (Hp) on vascular endothelial function in the patients with coronary heart disease (CHD). Methods The hospitalized CHD patients (n=104) with positive 14C-UBT were chosen from the Department of Cardiology of Daqing Longnan Hospital from Oct. 2010 to Feb. 2013. On the basis of routine treatment, the patients were given the triple therapy for eradicating Hp (amoxicillin+clarithromycin+lansoprazole) for 7 days and observed for 6 months. The levels of blood fat, thromboxane B2 (TXB2) and 6-keto-PGF1αwere detected before and after treatment. The endothelium-dependent flow-mediated dilation (FMD) was detected through observing the changes of brachial artery diameter (S1). Results The levels of TC and TXB2 decreased significantly after treatment [TC:(4.98± 1.20) mmol/L vs. (5.43±1.87) mmol/L;TXB2:(240±41) pg/ml vs. (282±66) pg/mL], and 6-keto-PGF1αand CI increased significantly [6-keto-PGF1α:(299±69) pg/ml vs. (217±64) pg/mL;S1:(7.86±0.39)%vs. (4.87 ±0.26)%, P<0.05]. Conclusion The triple therapy for eradicating Hp can ameliorate the vascular endothelial function in CHD patients with Hp infection.
Keywords：Coronary heart diseaseHelicobacter pyloriThromboxane B26-keto-PGF1αEndothelium-dependent flow-mediated dilationEndothelial function
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 505-506,539 )